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Abstract: Venous thromboembolism (VTE) is a common complication among hospitalized 
patients. Pharmacological thromboprophylaxis has emerged as the cornerstone for VTE preven-
tion. As trials on thromboprophylaxis in medical patients have proven the efﬁ  cacy of both low-
molecular-weight heparins (LMWHs) and unfractionated heparin (UFH), all acutely medical ill 
patients should be considered for pharmacological thromboprophylaxis. Unlike in the surgical 
setting where the risk of associated VTE attributable to surgery is well recognized, and where 
widespread use of pharmacological thromboprophylaxis and early mobilization has resulted in 
signiﬁ  cant reductions in the risk of VTE, appropriate VTE prophylaxis is under-used in medical 
patients. Many reasons for this under-use have been identiﬁ  ed, including low perceived risk of 
VTE in medical patients, absence of optimal tools for risk assessment, heterogeneity of patients 
and their diseases, and fear of bleeding complications. A consistent group among hospitalized 
medical patients is composed of elderly patients with impaired renal function, a condition 
potentially associated with bleeding. How these patients should be managed is discussed in 
this review. Particular attention is devoted to LMWHs and fondaparinux and to measures to 
improve the safety and the efﬁ  cacy of their use.
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Thromboembolism among hospitalized medical 
patients: an underestimated problem?
Venous thromboembolism (VTE), a potentially life-threatening disease which 
includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a com-
mon complication among hospitalized patients. Its incidence in medical patients 
may be as high as 20% in selected high-risk medical patients who are not receiving 
prophylaxis (Geerts et al 2004). Unlike in the surgical setting where the risk of 
associated DVT attributable to surgery is well recognized, and where widespread 
use of pharmacological thromboprophylaxis and early mobilization has resulted 
in signiﬁ  cant reductions in the risk of VTE (Geerts et al 2004), appropriate VTE 
prophylaxis is under-utilized in medical patients.
PE is proven by autopsy studies in about 10% of all in-hospital deaths (Alikan 
et al 2004). About 80% of these cases occurred in patient older than 60 years, and 
most such patients had not undergone surgery (Goldhaber et al 1982). In addition 
to the morbidity and mortality associated with inappropriate lack of use of throm-
boprophylaxis, a delay in the recognition and treatment of DVT or PE will increase 
both the morbidity and mortality attributable to these disorders. Nonetheless prompt 
diagnosis of acute VTE can be difﬁ  cult. Autopsy studies have proved that DVT can 
lead to PE without any warning symptoms (Lindblad et al 1991). Furthermore, clinical 
symptoms, when present, are often misleading: in a review of 67 cases of fatal PE, Clinical Interventions in Aging 2007:2(2) 238
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the diagnosis of PE was made in only 45% of cases before 
death (Pineda et al 2001). 
Evidence for pharmacological 
prophylaxis
Compared with surgical studies, trials of thromboprophylaxis 
in medical patients often have smaller sample sizes and 
other methodological limitations. Nevertheless, both 
low-molecular-weight heparins (LMWHs) and unfractionated 
heparin (UFH) appear to reduce the incidence of DVT in 
hospitalized, elderly patients. Their efﬁ  cacy compared with 
placebo has been conﬁ  rmed in systematic reviews (Mismetti 
et al 2000; Imberti and Prisco 2005) and large studies.
The MEDENOX trial (Samama et al 1999) was a 
randomized, double-blind study was designed to evaluate 
the efﬁ  cacy and safety of enoxaparin versus placebo in 
medical patients older than 40 years, expected to stay in 
hospital for at least 6 days (Table). Patients were excluded if 
they had a serum creatinine level above 1.7 mg/dL. Patients 
were randomly assigned to receive 40 mg of enoxaparin, 
20 mg of enoxaparin, or placebo subcutaneously once daily 
for 6–14 days. About half of the enrolled patients were 
elderly. The primary efﬁ  cacy outcome, the composite of 
distal and proximal asymptomatic DVT detected by routine 
venography, symptomatic VTE, and fatal PE up to day 14, 
was 5.5% in the group that received 40 mg of enoxaparin 
compared with 14.9% in the placebo group, a signiﬁ  cant 
difference. There was no signiﬁ  cant difference in the in-
cidence of VTE between the group that received 20 mg of 
enoxaparin (15.0%) and the placebo group. The incidence of 
major bleeding during the study did not differ signiﬁ  cantly 
between the placebo group and either enoxaparin groups. 
Mortality rates at day 90 were similar.
The PREVENT study (Leizorovicz et al 2004), a 
randomized, double-blind, placebo-controlled study, was 
designed to evaluate the efﬁ  cacy and safety of dalteparin 
versus placebo in medical patients older than 40 years, 
expected to stay in hospital for at least 4 days, and not 
immobilized for more than 3 days (Table 1). Patients were 
randomly assigned to receive 5000 IU of dalteparin or 
placebo subcutaneously once daily for 14 days. The primary 
efﬁ  cacy outcome, the composite of proximal asymptomatic 
DVT detected by routine ultrasonography, symptomatic 
VTE, fatal PE, and sudden death up to day 21, was to 2.7% 
in the dalteparin group compared with 4.96% in the placebo 
group, a signiﬁ  cant difference. The incidence of major bleed-
ing during the study was low and similar in both groups 
(0.49% vs 0.16%, respectively). Mortality rates at day 90 
were similar. Patients were excluded if they had a serum 
creatinine level above 2.0 mg/dL. Age more than of 75 years 
was present in 33% of patients.
In contrast to MEDENOX, which largely evaluated the 
impact of thromboprophylaxis on venographically detected 
and largely asymptomatic distal DVT, in PREVENT the 
major component of the composite efﬁ  cacy outcome was 
asymptomatic proximal DVT assessed by systematic 
screening with compression ultrasound. Compression 
ultrasonography is a non-invasive, highly sensitive technique 
for the diagnosis of symptomatic proximal DVT, and in many 
countries is now the technique of ﬁ  rst choice for the diagnosis 
of DVT in clinical practice (Bressollette et al 2001; Zierler 
2004; Blann and Lip 2006).
Guidelines adherence
Based on this body of evidence the panel of experts of The 
Seventh Consensus Conference on Antithrombotic Therapy 
of the American College of Chest Physicians (ACCP) 
recommends “prophylaxis with LDUH or LMWHs in acutely 
ill medical patients who have been admitted to the hospital 
with congestive heart failure or severe respiratory disease, 
or who are conﬁ  ned to bed and have one or more additional 
risk factors, including active cancer, previous VTE, sepsis, 
acute neurologic disease, or inﬂ  ammatory bowel disease” 
(Geerts et al 2004). Only UFH, enoxaparin, and dalteparin 
are approved for venous thromboprophylaxis in most 
jurisdictions. 
In spite of the evidence for the beneﬁ  ts of thrombopro-
phylaxis in medically ill patients, data indicate an under-
use of thromboprophylaxis in these patients. In a 1-year 
historical cohort study (Arnold et al 2001), 253 cases of 
acute VTE were objectively diagnosed. In 44 out 65 (67.7%) 
cases of VTE for which thromboprophylaxis had been 
indicated, inadequate prophylaxis was administered. The 
main reason for inadequacy was most often the omission 
of thromboprophylaxis. The DVT FREE study (Goldhaber 
et al 2004) is a prospective multicenter registry of patients 
with ultrasound-conﬁ  rmed acute DVT. Of the 2726 patients 
who had their DVT diagnosed while in the hospital, only 
1147 (42%) received prophylaxis within 30 days before 
diagnosis. Non-surgical patients were much less likely to 
receive prophylaxis compared with surgical patients. RIETE 
is a Spanish registry of consecutively enrolled patients with 
objectively conﬁ  rmed, symptomatic acute VTE (Monreal 
et al 2004). This study demonstrated underuse of thrombopro-
phylaxis in acutely medical ill patients; only 28% of medical 
patients with DVT had received thromboprophylaxis, Clinical Interventions in Aging 2007:2(2) 239
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Table 1 The main features and results of the three most important randomized trials on pharmacological prophylaxis in medical patients
 MEDENOX  PREVENT  ARTEMIS
Eligibility criteria
Age  40  40  60
Bed rest  6 days  4 days  4 days
Disease  Acute heart failure;   Acute heart failure;   Acute heart failure; 
  Acute respiratory   Acute respiratory   acute or chronic lung 
  illness; or   illness; or   disease, acute 
  Infection; Bone/joint,   Infection; Bone/joint,   infectious or 
 Inﬂ  amed bowel plus  Inﬂ  amed bowel plus  inﬂ  ammatory disease
VTE risk  1 (>75 y, cancer,   1 (>75 y, cancer, 
  previous VTE, obesity,   previous VTE, obesity, 
  varicose veins,   varicose veins, 
  hormones, chronic   hormones, chronic 
  heart or lung failure)  heart or lung failure)
Treatments
  Enoxaparin 40 mg  Dalteparin 5000 UI  Fondaparinux 2.5 mg
  Enoxaparin 20 mg  Placebo  Placebo
 Placebo
End points
At Day  14  21  15
  Venographic distal or   Proximal   Venographic distal or 
  proximal DVT  ultrasonographic DVT  proximal DVT
plus  Symptomatic VTE  Symptomatic VTE  Symptomatic VTE
plus  Fatal PE  Fatal PE and sudden   Fatal PE
   death
Safety  Major bleeding  Major bleeding  Major bleeding
  Death at day 90  Death at day 90  Death at day 90
Results 
  Enoxaparin 40 mg 5.5%  Dalteparin 2.7%  Fondaparinux 5.6%
  Placebo 14.9%  Placebo 4.96%  Placebo 10.5 %
  p = 0.001  p = 0.0015  p = 0.029
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism;  VTE, venous thromboembolism. 
compared with 67% of surgical patients. Many reasons for 
this under-use have been identiﬁ  ed, including low perceived 
risk of VTE in medical patients, absence of optimal tools for 
risk assessment, heterogeneity of patients and their diseases, 
and fear of bleeding complications (Kakkar et al 2004). 
Unfractionated heparin 
and low-molecular-weight heparins
LMWHs are being used with increasing frequency for medical 
thromboprophylaxis (Hirsh and Raschke 2004) despite a lack 
of evidence that they provide either superior antithrombotic 
efﬁ  cacy or improved safety when compared with low-dose 
UFH (Mismetti et al 2000; Alikan and Cohen 2003). The UFH 
in current clinical use is a polydispersed unmodiﬁ  ed hepa-
rin, with molecular weight ranging from 3000 to 30,000 Da 
and a mean molecular weight of approximately 15,000 Da. 
Most of the limitations of unfractionated heparin (such as 
unpredictable anticoagulant response, heparin resistance, 
heparin-induced thrombocytopenia, and osteopenia) are 
explained, at least in part, by its charge mediated non-speciﬁ  c 
binding to cell surfaces and plasma proteins. LMWHs are 
fragments derived from controlled enzymatic or chemical 
depolymerization of heparin. LMWH molecules weigh 
about one third of UFH, usually in the range of 4000–5000 
Da (every molecule is made of about 15 monosaccharide 
units). Because the process of heparin depolymerization is 
controlled, different heparin fragments with speciﬁ  c phar-
macokinetic and anticoagulant properties can be produced. 
Fragments derived from heparin depolymerization have 
lower binding afﬁ  nity for cells and proteins, the key prop-
erty that explains all anticoagulant, pharmacokinetic, and 
biological characteristic of LMWHs. Clinical Interventions in Aging 2007:2(2) 240
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Fondaparinux
Fondaparinux is a synthetic highly sulfated pentasaccharide 
which has a sequence derived from the minimal antithrombin 
binding region of heparin. Fondaparinux binds to antithrombin 
with high afﬁ  nity in a 1:1 stoichiometric and reversible manner 
(Olson et al 1992). It does not bind to other plasma proteins, 
blood cells, or platelet factor 4, making the risk of heparin-
induced thrombocytopenia very low (Warkentin et al 2005). 
In some jurisdictions, fondaparinux has been approved 
for the prophylaxis of DVT in patients undergoing various 
procedures including hip fracture surgery (often with extended 
or out of hospital administration), hip replacement surgery, 
knee replacement surgery, and high risk patients undergoing 
abdominal surgery. Fondaparinux has also been approved in 
Europe for the prophylaxis of DVT in medical patients, and 
for the treatment of both acute DVT and acute pulmonary 
embolism when administered in conjunction with warfarin 
sodium in the hospital (European Medicines Agency 2007).
Use of fondaparinux is supported by an impressive 
development program. The MATISSE DVT trial (Buller 
et al 2004a), a randomized double-blind trial, compared the 
efﬁ  cacy and safety of fondaparinux with that of enoxaparin 
followed by 3 months of vitamin K antagonist (target INR 
2.0–3.0) in the initial treatment of DVT. Patients were ran-
domly assigned to receive either fondaparinux as a single 
subcutaneous daily injection of 5 mg if body weight was 
<50 kg, 7.5 mg if body weight was 50–100 kg, and 10 mg 
if body weight was >100 kg, or enoxaparin as a twice-daily 
subcutaneous injection of 1 mg/kg. Both medications were 
administered for at least 5 days and until vitamin K antago-
nists induced an international normalized ratio (INR) >2.0. 
The primary efﬁ  cacy outcome, the 3-month incidence of 
symptomatic recurrent VTE, was 3.9% in the fondaparinux 
group compared with 4.1% in the enoxaparin group, a 
non-signiﬁ  cant difference. The incidences of major bleeding 
during the initial treatment period (1.1% vs 1.2%), deaths at 
3 months (3.8% vs 3.0%), and thrombocytopenia (0.6% in 
each group) were also similar. Patients were excluded if they 
had a serum creatinine level above 2.0 mg/dL. The mean age 
was less than 65 years in both groups.
The Matisse PE trial (Buller et al 2003), a randomized 
open-label trial, compared the efﬁ  cacy and safety of fonda-
parinux in the initial treatment of PE with that of unfraction-
ated heparin followed by 3 months of vitamin K antagonist 
(target INR 2.0–3.0). Patients were randomly assigned to 
receive either fondaparinux as a single subcutaneous daily 
injection of 5 mg if body weight was <50 kg, 7.5 mg if body 
weight was 50–100 kg, 10 mg if body weight was >100 kg 
without monitoring, or a continuous IV infusion of unfrac-
tionated heparin to achieve an a PTT ratio of 1.5–2.5. Both 
medications were given for at least 5 days and until the use 
of a vitamin K antagonist resulted in an INR >2.0. The inci-
dence of recurrent VTE was 3.8% in the fondaparinux group 
compared with 5.0% in the unfractionated heparin group, a 
non-signiﬁ  cant difference. The incidences of major bleeding 
(2.0% vs 2.4%), deaths (5.2% vs 4.4%), and thrombocytope-
nia (0.9% vs 1.2%) were also similar. Patients were excluded 
if they had a serum creatinine level above 2.0 mg/dL. The 
mean age was less than 65 years in both groups.
The recommended dose of fondaparinux for postoperative 
thromboprophylaxis is 2.5 mg administered by subcutaneous 
injection once daily to be initiated 6–8 hours after surgery. 
Administration before 6 hours after surgery has been asso-
ciated with an increased risk of major bleeding. The usual 
duration of administration is 5–9 days. In patients undergo-
ing hip fracture surgery extended prophylaxis for up to 24 
additional days is recommended. 
Special population: elderly patients 
with impaired renal function
Increasing age is a signiﬁ  cant risk factor for VTE. The 
Worcester DVT study (Anderson 1991) found that annual 
incidence of DVT increased exponentially with age from 17 
per 100,000 persons/year for those between the ages of 40 
and 49 to 232 per 100,000 persons/year for those between 
the ages of 70 and 79. The Longitudinal Investigation of 
Thromboembolism Etiology (Tsai et al 2002), based on a 
general US adult population, found an increasing incidence 
of ﬁ  rst VTE with age, with a hazard ratio of 1.7 (95% con-
ﬁ  dence interval [CI]: 1.5–2.0) for every decade of life after 
age 55 years. Age is also a risk factor for increased risk of 
death in patients with PE; the mortality due to PE during 
hospital stay is 21% in patients older than 65 years and may 
be as low as 2% in patients younger than 40 years (White 
2003). Immobilization as in chronically bedridden nursing 
home residents (Heit et al 2000; Gatt et al 2004) and im-
mobilization associated with an acute illness are recognized 
relevant risk factors for the development of DVT in elderly 
patients even before hospital admission. In a prospective 
study (Oger et al 2002) of 234 consecutive medical patients 
who underwent venous compression ultrasonography within 
48 hours of admission, the prevalence of asymptomatic DVT 
was 17.8% in patients older than 80 years and 0% in patients 
younger than 55 years. 
In addition to a higher risk of hospitalization, elderly 
patients frequently harbour unsuspected renal failure Clinical Interventions in Aging 2007:2(2) 241
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(El Nahas 2005). Data describing the safety and efﬁ  cacy 
of LMWHs in patients with renal failure are inconsistent. 
The ACCP panel of experts’ recommendations are vague: 
“for each of the antithrombotic agents, we recommend that 
clinicians consider the manufacturer’s suggested dosing 
guidelines. We recommend consideration of renal impair-
ment when deciding on doses of LMWH, fondaparinux, and 
other antithrombotic drugs that are cleared by the kidneys, 
particularly in elderly patients and those who are at high risk 
for bleeding” (Geerts et al 2004). 
Impaired renal function is an important risk factor for 
bleeding during anticoagulation treatment (Levine et al 
2004). Assessing the elderly for renal failure is problematic 
since the creatinine level may be misleading, as total creati-
nine decreases with age as muscle mass decreases. Often, a 
serum creatinine level within the normal range erroneously 
classiﬁ  es elderly patients as having a normal renal function. 
The frequent overestimation of renal function could be 
avoided by estimating the creatinine clearance (CrCl) using 
equations such as the Cockcroft-Gault (CG) or Modiﬁ  ca-
tion of Diet in Renal Disease (MDRD) (Stevens et al 2006). 
Though the MDRD equation has many advantages (height 
or weight are not needed for calculation), it has not been 
validated in people older than 70 years. Some of the studies 
that compared the two equations in this patient population 
have shown that the MDRD equation may underestimate the 
CrCl in elderly patients (Pedone et al 2006). Nonetheless, 
these results are not conclusive (Verhave et al 2005), and 
their clinical signiﬁ  cance is uncertain in the absence of data 
about clinical outcomes that would derive from the use of the 
MDRD equation. However, when CrCl is properly evaluated 
by these equations, about 60% of critical medical patients 
aged over 70 years will have some degree of renal impair-
ment (Clase et al 2002). As they are cleared by the kidneys, 
the main potential limitation of LMWH is the potential 
risk of bioaccumulation and bleeding when administered 
to patients with renal failure (Nagge et al 2002). However, 
there is emerging evidence that different LMWHs have dif-
ferent risks of bioaccumulation as LMWHs with the higher 
molecular weight are expected to be cleared mostly through 
the reticulo-endothelial system; it is also not clear which 
value of CrCl is a threshold below which there is a risk of 
bioaccumulation (Nagge et al 2002; Lim et al 2005).
Elderly patients with renal failure have been systemati-
cally excluded from most large randomized clinical trials on 
thrombosis prophylaxis and VTE treatment, as advanced age, 
age-related renal function impairment, and polypharmacy are 
potentially associated with bleeding. It is therefore important 
to design clinical trials for each anticoagulant with the aim of 
examining the safety of multiple injections in elderly patients 
with varying severity of renal failure.
Tinzaparin
Tinzaparin has an average molecular weight of 5500–7500 
Da, and the following properties (Tinzaparin prescribing 
information 2006) – onset of action: 2–3 hours, distribu-
tion: 3–5 L, half-life elimination: 3–4 hours, metabolism: 
partially metabolized by desulphation and depolymerization, 
bioavailability: 87%, time to peak: 4–5 hours, excretion: 
urine, anti-Xa to anti-IIa activity ratio, 1.9.
There is evidence that therapeutic doses of tinzaparin 
have a favorable safety proﬁ  le in elderly patients even with 
renal failure. 
A prospective study (Siguret et al 2000) evaluated wheth-
er tinzaparin accumulated in patients older than 70 years of 
age. Thirty patients (mean age 87 years) suffering from acute 
thromboembolic disorders were treated with a body-weight 
dose of tinzaparin (175 anti-Xa IU/Kg) once daily over 
10 days. Patients with a CrCl lower than 20 mL/min were 
excluded. The mean anti-Xa activity measured 5 hours after 
the second injection of tinzaparin did not signiﬁ  cantly vary 
from day 2 to day 10. No correlation was observed between 
anti-Xa activity and CrCl. None of the patients developed 
heparin-induced thrombocytopenia and no major bleeding 
occurred.
The safety proﬁ  le of tinzaparin in very elderly patients 
whose CrCl was above 20 mL/min, and requiring full 
anticoagulation, was evaluated in another prospective study 
(Pautas et al 2002). Two-hundred patients, mean age 85 
years, mean creatinine clearance 51.2 ± 22.9 mL/min, were 
treated with a body-weight dose of tinzaparin (175 anti-Xa 
IU/Kg) once daily up to 30 days. Plasma anti-Xa activity 
levels were regularly measured throughout the treatment 
period. Three major bleeding episodes (1.5%) were reported. 
Heparin-induced thrombocytopenia was conﬁ  rmed in two 
patients (1%). No correlation was found between anti-Xa 
activity and CrCl or age. 
These ﬁ  ndings suggest that the larger molecular size and 
increased charge of tinzaparin make it less likely to accumu-
late than other LMWHs in patients with mild-to-moderate 
renal insufﬁ  ciency (CrCl >30 mL/min).
The manufacturer of tinzaparin does not recommend 
any dose adjustment in elderly renally impaired patients 
(Tinzaparin prescribing information 2006). 
In cases of serious bleeding or large overdose, protamine 
sulfate (1% solution) can be given by slow IV infusion at a Clinical Interventions in Aging 2007:2(2) 242
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dose of 1 mg protamine for every 100 anti-Xa IU of tinza-
parin given. A second infusion of 0.5 mg protamine sulfate 
per 100 anti-Xa IU of tinzaparin may be administered if the 
aPTT measured 2–4 hours after the ﬁ  rst infusion remains pro-
longed. Even with the additional dose of protamine, the aPTT 
may remain more prolonged than would usually be found fol-
lowing administration of protamine to reverse unfractionated 
heparin. Protamine does not completely neutralize tinzaparin 
sodium anti-Xa activity (maximum about 60%).
Dalteparin
Dalteparin has an average molecular weight of 4000–6000 Da, 
and the following properties (Dalteparin prescribing informa-
tion 2006): onset of action: 1–2 hours, duration: >12 hours, 
half-life elimination (route dependent): 2–5 hours, time to 
peak, serum: 4 hours, anti-Xa to anti-IIa activity ratio, 2.5.
Studies of dalteparin in patients with old age or with renal 
failure are few and all recently published (Kucher et al 2005; 
Shprecher et al 2005; Tincani et al 2006). Available data 
suggest that administration of repeated prophylactic doses 
of dalteparin in patients with renal failure is not associated 
with accumulation and dose reduction is not needed. 
There are less data to guide therapeutic doses of dalteparin 
in patients with renal impairment. A small study (Shprecher 
et al 2005 ) did not ﬁ  nd any difference in anti -Xa activity in 
eleven patients with renal failure with respect to 11 patients 
with normal renal function, after subcutaneous induction of 
anticoagulation with doses of 100 IU/kg every 12 hours.
In a prospective single-center cohort study conducted in 
an intensive care unit (Rabbat et al 2005), 19 patients aged 
62.7 ± 13.2 years with an APACHE II score of 23.5 ± 9.4, and 
a creatinine clearance 30 mL/min or higher, were enrolled. 
Each patient received 5000 IU dalteparin subcutaneously 
each day for thromboprophylaxis. Peak anti-Xa levels, mea-
sured 4 hours post dalteparin dose on 113 occasions, showed 
no evidence of bioaccumulation of dalteparin. 
In a retrospective, post-hoc analysis of PREVENT data 
(Kucher et al 2005), dalteparin was shown to be both effec-
tive and safe for thromboprophylaxis in hospitalized patients 
75 years or older compared with placebo. The use of dalte-
parin reduced VTE events by 52%, and was not associated 
with an increase of major hemorrhage rates (1.1% in the 
dateparin group vs 0.7% in the placebo group, respectively, 
p = 0.12). Unfortunately patients with a serum creatinine 
level above 2.0 mg/dL were excluded, and CrCl was not 
directly measured.
The results of a prospective, cohort study (Tincani et al 
2006) have shown that dalteparin thromboprophylaxis, in 
patients aged 65 years or older, admitted with an acute 
medical illness requiring immobilization for at least 3 days, 
who have renal impairment is associated with a low risk of 
both bioaccumulation and bleeding. The study enrolled 115 
consecutive patients with a mean age of 83 years, who had 
a serum creatinine 1.2 mg/dL (females), or 1.4 mg/dL 
(males). Ninety-three patients judged to be at high thrombo-
embolic risk (patients older than 75 years, with active cancer 
or previous venous thromboembolism) received dalteparin 
5000 IU daily; the other 22, considered at low risk, received 
2500 IU daily. Dalteparin was given for 6 days. Anti-Xa 
activity was determined on day 1, before the ﬁ  rst dalteparin 
dose, and on day 6, 4 hours after its administration. A com-
plete compression ultrasound examination of leg veins was 
performed at admission and at discharge. The primary study 
end point was the anti-Xa activity levels at day 6. Second-
ary end points were: the occurrence of hemorrhage during 
the in-hospital stay, objectively conﬁ  rmed symptomatic 
(limb pain and swelling) DVT, and objectively conﬁ  rmed 
asymptomatic DVT. There were no major bleeding events, no 
symptomatic thromboembolic events, and no asymptomatic 
DVT was recorded (95% CI 0%–2.5%). Of the 115 patients, 
3 (2.7%) had minor hemorrhage (95% CI 0.6%–6.7%). In 
all 3 cases anti-Xa activity was undetectable at the time of 
the bleed. There were no cases of VTE. There was also no 
relationship between the degree of renal impairment and 
the peak anti-Xa heparin level at day 6. As a small number 
of patients were enrolled, these preliminary data need to be 
validated by larger trials.
The manufacturer of dalteparin does not provide any 
information about dose adjustment in elderly or renally 
impaired patients. 
In cases of serious bleeding or large overdose, protamine 
sulfate (1% solution) can be given by slow IV infusion at a 
dose of 1 mg protamine for every 100 anti-Xa IU of dalte-
parin given. A second infusion of 0.5 mg protamine sulfate 
per 100 anti-Xa IU of dalteparin may be administered if the 
aPTT measured 2–4 hours after the ﬁ  rst infusion remains 
prolonged. Even with the additional dose of protamine, 
the aPTT may remain more prolonged than would usually 
be found following administration of protamine to reverse 
unfractionated heparin. In all cases, protamine does not 
completely neutralize dalteparin anti-Xa activity (maximum 
about 60%–75%) (Crowther et al 2002).
Enoxaparin
Enoxaparin has an average molecular weight of 4500 Da, and 
the following properties (Enoxaparin prescribing information Clinical Interventions in Aging 2007:2(2) 243
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2006) – onset of action: 3–5 hours, duration: ~12 hours, 
half-life elimination: 4.5–7 hours, excretion: urine, anti-Xa 
to anti-IIa activity ratio, 3.6.
To our knowledge, the safety and efﬁ  cacy of enoxaparin 
in elderly medical patients has been evaluated in only one 
study. 
The Enoxaparin in Medicine Study Group (Bergmann 
and Neuhart 1996), in a randomized, double-blind study, 
compared the efﬁ  cacy and safety of enoxaparin 20 mg versus 
UHF 5000 IU twice daily in 442 bedridden patients aged 65 
years or more, suffering from an acute medical illness, and 
not immobilized for more than 4 days. Both treatments were 
given for 10 days by subcutaneous injections. The studied 
population was at a moderate risk for VTE. The primary 
efﬁ  cacy outcome, the composite of DVT detected by daily 
ﬁ  brinogen uptake test, and clinical PE, was 4.8% in the 
enoxaparin group compared with 4.6% in the UHF group, a 
non-signiﬁ  cant difference. The incidence of major bleeding 
during the study was low and similar in both groups (0.9% 
vs 1.8%, respectively). Patients were excluded if they had 
a serum creatinine level above 2.0 mg/dL. The mean age 
was 83 years. 
Several studies have evaluated the safety administration 
of enoxaparin in patients with renal failure at therapeutic, 
adjusted, and prophylactic doses. A recent meta-analysis 
(Lim et al 2006) showed that in case of CrCl <30 mL/min, 
enoxaparin administered at: (a) standard therapeutic-dose is 
associated with supratherapeutic anti-Xa levels, and with a 
2- to 3-fold increased risk for major bleeding; (b) adjusted-
dose is associated to therapeutic anti-Xa levels without an 
increased risk for major bleeding to be conﬁ  rmed by further 
trials; (c) prophylactic-dose may bio accumulate.
The manufacturer of enoxaparin recommends, in patients 
with CrCl <30 mL/min, a reduced dose of 30 mg once daily 
for DVT prophylaxis, and of 1 mg/kg once daily for VTE 
treatment.
In cases of serious bleeding or large overdose, protamine 
sulfate (1% solution) can be given by slow IV infusion at 
a dose of 1 mg protamine for every 1 mg of enoxaparin, if 
enoxaparin was administered in the previous 8 hours. An 
infusion of 0.5 mg protamine per 1 mg of enoxaparin may 
be administered if enoxaparin was administered more than 
8 hours previous to the protamine administration. A second 
infusion of 0.5 mg protamine sulfate per 1 mg of enoxaparin 
may be administered if the aPTT measured 2–4 hours after 
the ﬁ  rst infusion remains prolonged. After 12 hours of the 
enoxaparin injection, protamine administration may not be 
required. However, even with higher doses of protamine, the 
aPTT may remain more prolonged than under normal condi-
tions found following administration of heparin. In all cases, 
protamine does not completely neutralize enoxaparin anti-Xa 
activity (maximum about 60%) (Crowther et al 2002).
Fondaparinux
Fondaparinux has a molecular weight of 1728 Da, and the 
following properties (Fondaparinux prescribing information 
2006): 100% bioavailability after subcutaneous injection, 
with peak serum concentrations reached approximately 
3 hours post-dose. Its half-life of 17 hours allows once 
daily dosing. Fondaparinux does not prolong the activated 
partial thromboplastin time (aPTT), prothrombin time, or 
bleeding time. As PT and aPTT are insensitive measures of 
fondaparinux activity, antifactor Xa activity of fondaparinux 
can be measured by the assay if fondaparinux is used as the 
calibrator. Most of an administered dose of fondaparinux is 
cleared by the kidney, and excreted unchanged in the urine, 
with an elimination half-life of 17–21 hours. Clearance of this 
drug is reduced in subjects with reduced CrCl. The clearance 
of fondaparinux is approximately 25% lower in patients with 
mild renal impairment (CrCl 50–80 mL/min), approximately 
40% lower in patients with moderate renal impairment (CrCl 
30–50 mL/min), and approximately 55% lower in patients 
with severe renal impairment (CrCl <30 mL/min) compared 
with patients with normal renal function. Fondaparinux 
elimination is prolonged in patients older than 75 years. In 
this group of patients, the clearance is approximately 25% 
lower compared with patients younger than 65 years. Clear-
ance of fondaparinux is decreased by approximately 30% in 
patients weighing less than 50 kg. 
Fondaparinux has been studied for the prevention of VTE 
in elderly patients with acute medical illnesses.
The ARTEMIS trial (Cohen et al 2006), a randomized, 
double-blind study, was designed to evaluate the efﬁ  cacy 
and safety of fondaparinux with that of placebo in prevent-
ing VTE in medical patients 60 years of age considered to 
be at moderate risk for VTE (Table). Patients were ran-
domly assigned to receive either fondaparinux as a single 
subcutaneous daily injection of 2.5 mg, or placebo. Both 
medications were administered within 48 hours of hospital 
admission and for a total of 6–14 days. The primary efﬁ  cacy 
outcome, the composite of asymptomatic DVT detected by 
routine venography and symptomatic VTE up to day 15, 
was 5.6% in the fondaparinux group compared with 10.5% 
in the placebo group, a signiﬁ  cant difference. The incidence 
of major bleeding during the study was 0.2% in both groups. 
Patients were excluded if they had a serum creatinine level Clinical Interventions in Aging 2007:2(2) 244
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above 2.0 mg/dL. The mean age was 75 years in both groups. 
In this study fondaparinux reduced the rate of venographi-
cally proven asymptomatic distal DVT. The importance of 
this observation is, however, called into question since the 
clinical relevance of distal asymptomatic DVT is uncertain, 
as documented by a recent review (Righini et al 2006), and 
by a retrospective, post-hoc analysis of PREVENT data 
(Vaitkus et al 2005). This analysis was conducted to compare 
the mortality rates in patients with asymptomatic proximal 
DVT, asymptomatic distal DVT, or no DVT. Mortality rates 
among patients with asymptomatic proximal DVT were 
13.75%, compared with 3.39% for patients with asymptom-
atic distal DVT and 1.92% for those without DVT.
Further studies comparing fondaparinux with UFH or 
LMWHs are awaited.
The manufacturer warns (a) not to use fondaparinux in 
patients with CrCl <30 mL/min, and in patients with body 
weight <50 kg; (b) to prescribe fondaparinux with caution 
in patients with moderate renal impairment (CrCl 30–50 
mL/min) and in patients older than 75 years. 
Periodic assessment of renal function is recommended, 
and fondaparinux should be discontinued immediately in 
patients who develop severe renal failure while on therapy. 
Fondaparinux is not inactivated by protamine and no antidote 
is known. 
Monitoring patients treated 
with LMWHs
None of the pivotal trials in which LMWHs were admin-
istered at prophylactic or therapeutic doses used routine 
anti-Xa heparin levels to monitor the LMWH and no clinical 
trials have clearly correlated the results of anti-Xa heparin 
monitoring with clinical outcomes. Nevertheless, experts 
suggest that monitoring the anticoagulant effect of LMWH 
might detect bioaccumulation thus improving the safety of 
LMWHs in selected populations.
Since LMWHs cause mild and unpredictable prolonga-
tion of the aPTT this test is inappropriate for monitoring 
their anticoagulant effect. If such monitoring is warranted, 
the only recommended test is a chromogenic anti-Xa activity 
assay test (Laposata et al 1998).
Because the aim of laboratory monitoring is to detect 
a possible bioaccumulation after multiple doses, the ﬁ  rst 
blood sample should be obtained at the third or fourth day of 
treatment if LMWHs are administered twice daily, and at the 
second or third day, in case of a single daily injection. 
As most of the trials did not adjust LMWHs doses 
according to anti-Xa activity, the level of anticoagulation that 
is most desirable for effective thromboprophylaxis or treat-
ment is unknown. Good examples are provided by the trials 
in which an adjusted-dose of enoxaparin was used with thera-
peutic intent in patients with acute coronary syndrome and 
with a CrCl 30 mL/min (Collet et al 2003; Montalescot et al 
2004). The dose adjustment was made when needed, aiming 
for a peak anti-Xa activity level between 0.5 and 1.0 IU/mL. 
The reduced dose was not associated with an increased rate 
of major bleeding, but the trade-off was an increased rate of 
myocardial infarction and of early mortality, in particular in 
case of anti-Xa activity lower than <0.5 IU/mL. 
Clinical management of elderly 
patients with renal failure
Today, the optimal way to use LMWHs in elderly patients 
hospitalized for an acute medical illness who are at increased 
risk of VTE and who have renal impairment is unsolved.
Before examining the measures to be adopted to minimize 
the risk for anticoagulant-related bleeding complications in 
this population of patients preliminary considerations are 
necessary. 
First of all, UFH remains the parenteral anticoagulant of 
choice in the treatment of patients with renal failure, at high 
risk of bleeding, and in whom rapid reversal of anticoagula-
tion may be required (Buller et al 2004). Unlike LMWHs, 
UFH has a short half-life after intravenous injection (1–2 
hours), can be reversed by protamine sulfate, and the clear-
ance is not dependent on renal excretion.
Second, we do not recommend routine monitoring of 
anti-Xa activity to detect accumulation.
Third, we recommend caution in using simple adjust-
ments in the dose of LMWH based on an estimated creatinine 
clearance since the impact of these adjustments on therapeutic 
effect is unknown.
Measures to improve the safety of LMWHs may include, 
on patient’s hospital admission:
1.  assessment of the bleeding risk (Beyth et al 1998), to 
identify patients in whom closer clinical surveillance 
may be warranted;
2.  avoidance of drugs that affect the bleeding risk;
3.  estimation of CrCl. The Modiﬁ  cation of Diet in Renal 
Disease Study equation may be preferred to the Cockcroft 
and Gault formula, as reliable weights are difﬁ  cult to 
obtain in elderly, bedridden patients;
4.  selection of LMWHs that are less likely to accumulate 
when CrCl is reduced. The following options seem safe 
and effective: weight-adjusted doses of tinzaparin and 
possibly dalteparin for the treatment of VTE; a dose of Clinical Interventions in Aging 2007:2(2) 245
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5000 IU once daily of dalteparin, of 5000 IU twice daily 
of UFH (monitoring platelets count), and of 30 mg once 
daily of enoxaparin for venous thromboprophylaxis.
For the initial treatment of VTE, vitamin K antagonist 
(VKA) therapy is started with LMWHs or UFH on the ﬁ  rst 
treatment day. The dose of VKA is adjusted to maintain 
the international normalized ratio between 2.0 and 3.0. 
LMWHs or UFH are continued for at least 5 days and until 
the international normalized ratio is greater than 2.0, for 2 
consecutive days. The duration of VKA treatment should 
be determined according to the ACCP recommendations 
(Buller et al 2004).
The optimal duration of the venous thromboprophylxis is 
not known for either chronically bedridden patients and for 
patients discharged from the hospital after an acute medical 
illness. Whether extended prophylaxis is warranted, and 
if so at what intensity and for what period, are unkown. 
This last issue has been evaluated by the investigators of 
the EXCLAIM study (NIH 2006), whose results should be 
soon available. 
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Appendix
To write this review we performed searches of the Medline 
electronic database to identify English-language studies on 
venous thromboembolism management in the elderly medical 
patient. Randomized controlled trials, observational studies, 
and prospective or retrospective cohort studies were eligible 
for the study. The references of the retrieved studies were 
reviewed for additional studies. The terms used were: deep 
vein thrombosis prevention or prophylaxis, venous thrombo-
embolism prevention or management, and elderly or geriatric 
patients. The search was completed on 31 October 2006.